Here's what the endometriosis economy rewards: delay, then monetization.
Not treatment. Not prevention. Not early diagnosis. The system profits from the moment a woman stops being believed by her first doctor and enters the long diagnostic gauntlet that can stretch five, ten, sometimes fifteen years. Every specialist referral, every imaging scan, every failed medication trial represents a revenue opportunity. The condition affects an estimated 10 percent of reproductive-age women, yet the industry structure incentivizes keeping them symptomatic and searching.
This isn't conspiracy thinking. It's how misaligned incentives work in healthcare.
Consider the diagnostic pathway. Endometriosis requires laparoscopic surgery to definitively confirm, making it expensive and invasive. But the system doesn't reward preventing it or catching it early through less invasive screening. Instead, it rewards the lengthy pre-surgical phase where women cycle through treatments, imaging, and specialist appointments. Each step generates revenue. The condition becomes a long-tail monetization event rather than a problem to solve quickly.
Meanwhile, women lose years of their lives. Career disruption, fertility complications, educational delays, relationship strain. The social costs are enormous. The system's costs are invisible to quarterly earnings reports.
The incentive structure also explains why symptom management dominates the treatment landscape. Hormonal birth control, NSAIDs, and various off-label medications keep women functional enough to continue working and paying, but rarely resolve the underlying condition. There's less financial incentive to develop or promote treatments that might actually eliminate endometriosis rather than perpetually manage it. A cure doesn't generate the same lifetime revenue as chronic symptom management.
Consider too how the condition is framed. Women describing severe pain are often labeled as catastrophizing or anxious rather than seriously ill. This framing isn't accidental. It justifies delay and makes the problem seem like an individual coping issue rather than a systemic medical failure. The same framing, we should note, doesn't apply to men with painful conditions. But when the patient population cannot effectively demand better, the incentive to provide better weakens considerably.
The recent visibility around endometriosis as a career-ending condition for some is positive. But visibility alone doesn't change incentive structures. It might actually accelerate another problematic cycle: the medicalization and professionalization of "living with" endometriosis rather than curing it. Wellness coaching, symptom-tracking apps, and self-care frameworks all have value. But they should supplement, not replace, genuine institutional investment in understanding and eliminating the disease.
Here's what would realign incentives: reimbursement structures that reward rapid diagnosis and definitive treatment outcomes rather than long diagnostic timelines. Insurance coverage that prioritizes early intervention. Research funding directed toward prevention and cure rather than incremental medication improvements. Professional credentialing systems that penalize providers for dismissing pain complaints. Legal accountability when diagnostic delay causes preventable harm.
None of these changes would happen naturally under current economic structures. They require external pressure.
Women with endometriosis shouldn't have to become patient advocates, health economists, and system reformers just to access care. But right now, the industry rewards everyone except them. It rewards providers for ordering more tests, pharmaceutical companies for developing symptom management drugs, and insurance companies for avoiding expensive interventions.
It does not reward getting women well.
When evaluating claims about women's health innovation and progress, readers should ask one question: Who actually benefits from the current timeline and approach? If the answer isn't "the women with the condition," then the system is working as designed. And designed systems are easier to change than to accidentally improve.